TriangleDISEASE & TREATMENT SETTING
Breast Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Breast Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- unresolved
- derivation note
- Derived from NCI topic(s): Breast Cancer; Breast Cancer Treatment During Pregnancy. Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
137 more-specific settings
Etcamah: metastatic Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration, ESR1 mutation →Arimidex: Breast cancer (adjuvant) →Enhertu: unresectable metastatic Breast cancer with HER2 positive, HER2 stated without a specific alteration after prior therapy →Femara: Breast cancer (adjuvant) →Femara: Breast cancer with HR positive →Ibrance: metastatic Breast cancer with HER2 negative →Perjeta: locally advanced Breast cancer with HER2 positive (neoadjuvant) →Taxotere: metastatic Breast Carcinoma (adjuvant) →Tykerb: metastatic Breast cancer with HR positive, HER2 stated without a specific alteration →Xeloda: metastatic Breast cancer →Avastin: metastatic Breast cancer with HER2 negative →Tecentriq: unresectable metastatic Breast cancer with PD-L1 stated without a specific alteration →Docetaxel: metastatic Breast cancer after prior therapy →Itovebi: metastatic Breast cancer with PIK3CA stated without a specific alteration, HR stated without a specific alteration, HER2 stated without a specific alteration (adjuvant) af →KADCYLA: Breast cancer with HER2 positive (neoadjuvant) after prior therapy →ABRAXANE: metastatic Breast cancer (adjuvant) after prior therapy →Enhertu: Breast cancer with HER2 positive (neoadjuvant) after prior therapy →FASLODEX: metastatic Breast cancer with HR positive, HER2 negative after prior therapy →Nerlynx: Breast cancer with HER2 positive (adjuvant) →CLIGAVYX: metastatic Breast cancer with HR positive, HER2 negative after prior therapy →IXEMPRA: metastatic Breast cancer after prior therapy →Paclitaxel: metastatic Breast cancer (adjuvant) after prior therapy →Ibrance: metastatic Breast cancer with HER2 Positive, HR positive, HER2 positive (maintenance) after prior therapy →Inluriyo: metastatic Breast cancer with HER2 stated without a specific alteration, ESR1 stated without a specific alteration after prior therapy →TRUQAP: metastatic Breast cancer with HR positive, HER2 negative, HR stated without a specific alteration, HER2 stated without a specific alteration, PIK3CA stated without a specif →TYKERB: metastatic Breast cancer with HER2 stated without a specific alteration after prior therapy →Ellence: Breast cancer (adjuvant) after prior therapy →OGIVRI: Breast cancer with HER2 stated without a specific alteration (adjuvant) after prior therapy →Verzenio: metastatic Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration, HR positive, HER2 negative after prior therapy →Doxorubicin Hydrochloride: Breast cancer (adjuvant) after prior therapy →Enhertu: Breast cancer with HER2 stated without a specific alteration, HER2 Positive, HER2 positive (neoadjuvant) →Ibrance: metastatic Breast cancer with PIK3CA stated without a specific alteration, HR positive, HER2 negative (adjuvant) after prior therapy →Afinitor: advanced Breast cancer with HER2 Negative, HER2 negative after prior therapy →Talzenna: metastatic Breast cancer with BRCA stated without a specific alteration, HER2 negative →Inluriyo: metastatic Breast cancer with HER2 negative, ESR1 stated without a specific alteration after prior therapy →MARGENZA: metastatic Breast cancer with HER2 stated without a specific alteration, HER2 positive after prior therapy →Phesgo: locally advanced Breast cancer with HER2 stated without a specific alteration, HER2 positive (neoadjuvant) →ZOLADEX: advanced Breast cancer →Kanjinti: Breast cancer with HER2 stated without a specific alteration (adjuvant) after prior therapy →CLIGAVYX: metastatic Breast cancer with HR positive, HER2 negative after prior therapy →Lynparza: Breast cancer with BRCA stated without a specific alteration, HER2 negative, HER2 stated without a specific alteration (neoadjuvant) after prior therapy →VEPPANU: metastatic Breast cancer with HER2 stated without a specific alteration, ESR1 stated without a specific alteration after prior therapy →Ibrance: metastatic Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration after prior therapy →Verzenio: metastatic Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration after prior therapy →Docetaxel: Breast cancer (adjuvant) →Ibrance: metastatic Breast cancer with HER2 Negative, HR stated without a specific alteration, HER2 stated without a specific alteration →KISQALI: metastatic Breast cancer with HR positive, HER2 negative after prior therapy →KEYTRUDA: Breast cancer (neoadjuvant) after prior therapy →IXEMPRA: metastatic Breast cancer →Fulvestrant: metastatic Breast cancer with HR positive, HER2 negative after prior therapy →EXEMESTANE: advanced Breast cancer after prior therapy →EXEMESTANE: Breast cancer (adjuvant) after prior therapy →Herceptin: Breast cancer with HER2 stated without a specific alteration →SOLTAMOX: Breast cancer (adjuvant) →BEIZRAY: Breast cancer (adjuvant) →Verzenio: metastatic Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration →TUKYSA: unresectable metastatic Breast cancer with HER2 positive, HER2 stated without a specific alteration after prior therapy →Lynparza: metastatic Breast cancer with BRCA stated without a specific alteration, HER2 negative (neoadjuvant) after prior therapy →DATROWAY: unresectable metastatic Breast cancer with PD-L1 stated without a specific alteration →AVGEMSI: metastatic Breast cancer (first-line) after prior therapy →Enhertu: Breast cancer with HER2 Positive, HER2 positive (neoadjuvant) →Kanjinti: Breast cancer with HER2 stated without a specific alteration →CLIGAVYX: advanced Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration, HR positive after prior therapy →Nerlynx: metastatic Breast cancer with HER2 positive, HER2 stated without a specific alteration after prior therapy →Trazimera: metastatic Breast cancer →Phesgo: locally advanced Breast cancer with HER2 positive (neoadjuvant) →Phesgo: metastatic Breast cancer with HER2 positive, HER2 stated without a specific alteration →Aromasin: Breast cancer (adjuvant) after prior therapy →CLIGAVYX: advanced Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration →ORSERDU: metastatic Breast cancer with HER2 stated without a specific alteration, ESR1 stated without a specific alteration after prior therapy →PIQRAY: metastatic Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration, PIK3CA stated without a specific alteration after prior th →ORSERDU: metastatic Breast cancer with HER2 negative, ESR1 stated without a specific alteration after prior therapy →TYKERB: metastatic Breast cancer with HER2 stated without a specific alteration →Enhertu: unresectable metastatic Breast cancer with HER2 positive, HER2 stated without a specific alteration (neoadjuvant) after prior therapy →HERZUMA: metastatic Breast cancer with HER2 stated without a specific alteration (first-line) after prior therapy →Femara: Breast cancer (adjuvant) after prior therapy →Femara: advanced Breast cancer after prior therapy →DATROWAY: unresectable metastatic Breast cancer with HR Positive, HER2 Negative, HR stated without a specific alteration, HER2 stated without a specific alteration after prior ther →HERZUMA: Breast cancer with HER2 stated without a specific alteration →ARIMIDEX: advanced Breast cancer (second-line) after prior therapy →SOLTAMOX: metastatic Breast cancer →Herceptin: metastatic Breast cancer with HER2 stated without a specific alteration (first-line) after prior therapy →BEIZRAY: metastatic Breast cancer after prior therapy →TRUQAP: metastatic Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration, PIK3CA stated without a specific alteration (adjuvant) aft →GEMCITABINE: metastatic Breast cancer (first-line) after prior therapy →PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND: metastatic Breast cancer (adjuvant) after prior therapy →KEYTRUDA QLEX: Breast cancer (neoadjuvant) after prior therapy →Herceptin Hylecta: Breast cancer with HER2 stated without a specific alteration (adjuvant) after prior therapy →PERJETA: metastatic Breast cancer with HER2 stated without a specific alteration, HER2 positive →FASLODEX: metastatic Breast cancer with HR positive, HER2 negative after prior therapy →OGIVRI: Breast cancer with HER2 stated without a specific alteration →MARGENZA: metastatic Breast cancer with HER2 positive, HER2 stated without a specific alteration after prior therapy →TRODELVY: unresectable metastatic Breast cancer with PD-L1 stated without a specific alteration (first-line) →Ontruzant: Breast cancer with HER2 stated without a specific alteration (adjuvant) after prior therapy →Talzenna: metastatic Breast cancer with BRCA stated without a specific alteration, HER2 negative, HER2 stated without a specific alteration →XELODA: metastatic Breast cancer after prior therapy →TYKERB: metastatic Breast cancer →Kanjinti: metastatic Breast cancer with HER2 stated without a specific alteration (first-line) after prior therapy →Femara: metastatic Breast cancer (first-line) →Trazimera: Breast cancer with HER2 stated without a specific alteration (adjuvant) →Aromasin: advanced Breast cancer after prior therapy →KADCYLA: metastatic Breast cancer with HER2 positive →OGIVRI: metastatic Breast cancer with HER2 stated without a specific alteration (first-line) after prior therapy →Verzenio: Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration (adjuvant) →Trazimera: metastatic Breast cancer with HER2 stated without a specific alteration (first-line) →DOCIVYX: Breast cancer (adjuvant) →Herceptin: Breast cancer with HER2 stated without a specific alteration (adjuvant) after prior therapy →KISQALI: Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration (adjuvant) →Fareston: metastatic Breast cancer →PERJETA: metastatic Breast cancer with HER2 positive, HER2 stated without a specific alteration →Ontruzant: metastatic Breast cancer with HER2 stated without a specific alteration (first-line) after prior therapy →Enhertu: unresectable metastatic Breast cancer with HER2 Positive, HER2 positive (first-line) →Nerlynx: Breast cancer with HER2 stated without a specific alteration (adjuvant) →Ellence: Breast cancer (adjuvant) after prior therapy →Fulvestrant: metastatic Breast cancer with HR positive, HER2 negative after prior therapy →Enhertu: unresectable metastatic Breast cancer with HER2 Low, HER2 stated without a specific alteration, HR stated without a specific alteration, HER2 low →DOCIVYX: metastatic Breast cancer after prior therapy →Afinitor: advanced Breast cancer with HER2 negative after prior therapy →Itovebi: metastatic Breast cancer with PIK3CA stated without a specific alteration, HR stated without a specific alteration, HER2 stated without a specific alteration (adjuvant) af →Herceptin Hylecta: metastatic Breast cancer with HER2 stated without a specific alteration (first-line) after prior therapy →Fulvestrant: advanced Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration, HR positive after prior therapy →KADCYLA: Breast cancer with HER2 positive (neoadjuvant) after prior therapy →Halaven: metastatic Breast cancer →Fulvestrant: advanced Breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration →Ontruzant: Breast cancer with HER2 stated without a specific alteration →ARIMIDEX: metastatic Breast cancer (first-line) →TRODELVY: unresectable metastatic Breast cancer with HR positive, HER2 negative, HR stated without a specific alteration, HER2 stated without a specific alteration after prior ther →Herceptin Hylecta: Breast cancer with HER2 stated without a specific alteration →Nerlynx: metastatic Breast cancer with HER2 positive, HER2 stated without a specific alteration after prior therapy →KADCYLA: metastatic Breast cancer with HER2 stated without a specific alteration, HER2 positive →recurrent Breast Cancer →metastatic Breast Cancer →localized Breast Cancer →advanced Breast Cancer →Stage 0 Breast Cancer →Stage IV Breast Cancer →Stage III Breast Cancer →
Study evidence for this setting
Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer
Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endo
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
Indication-specific source history
1996-05-14 · Taxotere (docetaxel) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-e38ed39a6944a5bd
- event date
- 1996-05-14
- event kind
- accelerated-approval
- drug or regimen
- Taxotere (docetaxel)
- source indication text
- Locally advanced or metastatic breast carcinoma that progressed during anthracycline-based therapy or relapsed during anthracycline-based adjuvant therapy
- match phrase
- breast carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-784ad31cc1e26911de81
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
1998-04-30 · Xeloda (capecitabine) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-d28c492fc3a1807f
- event date
- 1998-04-30
- event kind
- accelerated-approval
- drug or regimen
- Xeloda (capecitabine)
- source indication text
- Metastatic breast cancer resistant to paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and further anthracycline therapy is contraindicated
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-202c581a375484cc6391
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
1998-06-22 · Taxotere (docetaxel) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-d8329b64b7c25e79
- event date
- 1998-06-22
- event kind
- traditional-approval
- drug or regimen
- Taxotere (docetaxel)
- source indication text
- Locally advanced or metastatic breast carcinoma that progressed during anthracycline-based therapy or relapsed during anthracycline-based adjuvant therapy
- match phrase
- breast carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-784ad31cc1e26911de81
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2001-09-07 · Xeloda (capecitabine) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-b705cd2385eb8b56
- event date
- 2001-09-07
- event kind
- traditional-approval
- drug or regimen
- Xeloda (capecitabine)
- source indication text
- Metastatic breast cancer resistant to paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and further anthracycline therapy is contraindicated
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-202c581a375484cc6391
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2002-09-05 · Arimidex (anastrozole) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-480930fea8a51ae0
- event date
- 2002-09-05
- event kind
- accelerated-approval
- drug or regimen
- Arimidex (anastrozole)
- source indication text
- Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-bd9974d00fe3063899be
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2004-10-29 · Femara (letrozole) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-6c1b243d60874939
- event date
- 2004-10-29
- event kind
- accelerated-approval
- drug or regimen
- Femara (letrozole)
- source indication text
- Extended adjuvant treatment of early breast cancer in postmenopausal women who received 5 years of adjuvant tamoxifen
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-7d7e0b5accd3dbb8a76d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2005-09-16 · Arimidex (anastrozole) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-6d0181359a9383af
- event date
- 2005-09-16
- event kind
- traditional-approval
- drug or regimen
- Arimidex (anastrozole)
- source indication text
- Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-bd9974d00fe3063899be
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2005-12-28 · Femara (letrozole) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-e45e75eb7f08bc4a
- event date
- 2005-12-28
- event kind
- accelerated-approval
- drug or regimen
- Femara (letrozole)
- source indication text
- Postmenopausal women with HR positive early breast cancer
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-90c38048013f53e09335
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2008-02-22 · Avastin (bevacizumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-9a70a87771187a65
- event date
- 2008-02-22
- event kind
- accelerated-approval
- drug or regimen
- Avastin (bevacizumab)
- source indication text
- In combination with paclitaxel for patients who have not received chemotherapy for metastatic HER2 negative breast cancer
- match phrase
- breast cancer
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-9511165d623c9cba0382
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2010-01-29 · Tykerb (lapatinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-453bf4887c8a82cd
- event date
- 2010-01-29
- event kind
- accelerated-approval
- drug or regimen
- Tykerb (lapatinib)
- source indication text
- In combination with letrozole for post-menopausal women with HR-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-82cf35181d5af795f260
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2010-04-30 · Femara (letrozole) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-299fad2c21e5e200
- event date
- 2010-04-30
- event kind
- traditional-approval
- drug or regimen
- Femara (letrozole)
- source indication text
- Postmenopausal women with HR positive early breast cancer
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-90c38048013f53e09335
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2010-04-30 · Femara (letrozole) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-813f33c1bbb3097e
- event date
- 2010-04-30
- event kind
- traditional-approval
- drug or regimen
- Femara (letrozole)
- source indication text
- Extended adjuvant treatment of early breast cancer in postmenopausal women who received 5 years of adjuvant tamoxifen
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-7d7e0b5accd3dbb8a76d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2011-11-18 · Avastin (bevacizumab) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-b806fe8da1f663a6
- event date
- 2011-11-18
- event kind
- withdrawal
- drug or regimen
- Avastin (bevacizumab)
- source indication text
- In combination with paclitaxel for patients who have not received chemotherapy for metastatic HER2 negative breast cancer
- match phrase
- breast cancer
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-9511165d623c9cba0382
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2013-09-30 · Perjeta (pertuzumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-3368a31ef34c1894
- event date
- 2013-09-30
- event kind
- accelerated-approval
- drug or regimen
- Perjeta (pertuzumab)
- source indication text
- In combination with trastuzumab and docetaxel for neoadjuvant treatment of HER2-positive locally advanced inflammatory or early-stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early early breast cancer
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-2042250a3fdb5b1ba54d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2015-02-03 · Ibrance (palbociclib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-a80e503b68697372
- event date
- 2015-02-03
- event kind
- accelerated-approval
- drug or regimen
- Ibrance (palbociclib)
- source indication text
- In combination with letrozole for postmenopausal women with ER-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-f1c1411e2a103eb4331d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2017-03-31 · Ibrance (palbociclib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-87e1462b06d274dc
- event date
- 2017-03-31
- event kind
- traditional-approval
- drug or regimen
- Ibrance (palbociclib)
- source indication text
- In combination with letrozole for postmenopausal women with ER-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-f1c1411e2a103eb4331d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2017-12-20 · Perjeta (pertuzumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-2b9e2c1e5af009aa
- event date
- 2017-12-20
- event kind
- traditional-approval
- drug or regimen
- Perjeta (pertuzumab)
- source indication text
- In combination with trastuzumab and docetaxel for neoadjuvant treatment of HER2-positive locally advanced inflammatory or early-stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early early breast cancer
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-2042250a3fdb5b1ba54d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2018-12-06 · Tykerb (lapatinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-c4e6cfae42965d72
- event date
- 2018-12-06
- event kind
- traditional-approval
- drug or regimen
- Tykerb (lapatinib)
- source indication text
- In combination with letrozole for post-menopausal women with HR-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-82cf35181d5af795f260
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2019-03-08 · Tecentriq (atezolizumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-98b25c211d8d5105
- event date
- 2019-03-08
- event kind
- accelerated-approval
- drug or regimen
- Tecentriq (atezolizumab)
- source indication text
- In combination with paclitaxel protein-bound for unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering = 1% of the tumor area), as determined by an FDA-approved test.
- match phrase
- breast cancer
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-fdd6a6634a93158b671b
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2019-12-20 · Enhertu (Fam-trastuzumab deruxtecan-nxki) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-b9b393513c07e5b2
- event date
- 2019-12-20
- event kind
- accelerated-approval
- drug or regimen
- Enhertu (Fam-trastuzumab deruxtecan-nxki)
- source indication text
- Adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-9296042d51d58533d9fc
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-10-06 · Tecentriq (atezolizumab) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-c30c5f38918960a6
- event date
- 2021-10-06
- event kind
- withdrawal
- drug or regimen
- Tecentriq (atezolizumab)
- source indication text
- In combination with paclitaxel protein-bound for unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering = 1% of the tumor area), as determined by an FDA-approved test.
- match phrase
- breast cancer
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-fdd6a6634a93158b671b
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2022-05-04 · Enhertu (Fam-trastuzumab deruxtecan-nxki) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-4bf55aa1fc8f6f4b
- event date
- 2022-05-04
- event kind
- traditional-approval
- drug or regimen
- Enhertu (Fam-trastuzumab deruxtecan-nxki)
- source indication text
- Adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting
- match phrase
- breast cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-9296042d51d58533d9fc
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-01-17 · datopotamab deruxtecan-dlnk · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- notice-c47d1848e489db06
- event date
- 2025-01-17
- event kind
- approval-notification
- drug or regimen
- datopotamab deruxtecan-dlnk
- source indication text
- FDA approved datopotamab deruxtecan-dlnk, a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic, hormone receptor -positive, human epidermal growth factor receptor 2 -negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
- match phrase
- breast cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-718ebee3ee60ca74
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-01-27 · fam-trastuzumab deruxtecan-nxki · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- notice-fc2e8fba5106d4f3
- event date
- 2025-01-27
- event kind
- approval-notification
- drug or regimen
- fam-trastuzumab deruxtecan-nxki
- source indication text
- FDA approved fam-trastuzumab deruxtecan-nxki for unresectable or metastatic hormone receptor -positive, HER2-low or HER2-ultralow breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
- match phrase
- breast cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-6c8690a10014b840
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-09-25 · imlunestrant · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- notice-0b162a998d6a5e47
- event date
- 2025-09-25
- event kind
- approval-notification
- drug or regimen
- imlunestrant
- source indication text
- FDA approved imlunestrant, an estrogen receptor antagonist, for adults with estrogen receptor -positive, human epidermal growth factor 2 -negative, estrogen receptor-1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
- match phrase
- breast cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-e6329c4a9f1a5704
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-12-15 · fam-trastuzumab deruxtecan-nxki with pertuzumab · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- notice-bcd1c984343331ac
- event date
- 2025-12-15
- event kind
- approval-notification
- drug or regimen
- fam-trastuzumab deruxtecan-nxki with pertuzumab
- source indication text
- FDA approved fam-trastuzumab deruxtecan-nxki in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer as determined by an FDA-approved test.
- match phrase
- breast cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-838a85e7ab9c5846
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-05-01 · vepdegestrant · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- notice-def544a6d91f534e
- event date
- 2026-05-01
- event kind
- approval-notification
- drug or regimen
- vepdegestrant
- source indication text
- FDA approved vepdegestrant, a heterobifunctional protein degrader, for adults with estrogen receptor -positive, human epidermal growth factor receptor 2 -negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
- match phrase
- breast cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-139bc569cd69b40c
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-05-15 · fam-trastuzumab deruxtecan-nxki · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- notice-98e9bd699133ea26
- event date
- 2026-05-15
- event kind
- approval-notification
- drug or regimen
- fam-trastuzumab deruxtecan-nxki
- source indication text
- FDA approved fam-trastuzumab deruxtecan-nxki for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab, for the neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab and taxane-based treatment.
- match phrase
- breast cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-a25466af65cfcdc1
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-05-22 · datopotamab deruxtecan-dlnk · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- notice-4e4bb7b26ead1f4e
- event date
- 2026-05-22
- event kind
- approval-notification
- drug or regimen
- datopotamab deruxtecan-dlnk
- source indication text
- FDA approved datopotamab deruxtecan-dlnk for adult patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.
- match phrase
- breast cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-06e75bbbea9cc2b5
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-06-24 · sacituzumab govitecan-hziy · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- notice-751ba0fbc8cc4d64
- event date
- 2026-06-24
- event kind
- approval-notification
- drug or regimen
- sacituzumab govitecan-hziy
- source indication text
- FDA approved sacituzumab govitecan-hziy for two indications in adults with triple-negative breast cancer . The first indication, supported by ASCENT-03, is for sacituzumab govitecan-hziy as a single agent for the first-line treatment of adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. The second indication, supported by ASCENT-04/KEYNOTE D-19, is for sacituzumab govitecan-hziy in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 as determined by an FDA-authorized test.
- match phrase
- breast cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-49e2a73345425f2f
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-06-24 · palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- notice-77f70ab5f14159d8
- event date
- 2026-06-24
- event kind
- approval-notification
- drug or regimen
- palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy
- source indication text
- FDA approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
- match phrase
- breast cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-679b968656ef28cf
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-07-14 · gedatolisib with fulvestrant, with or without palbociclib · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- notice-95a1c2aa93f1fd39
- event date
- 2026-07-14
- event kind
- approval-notification
- drug or regimen
- gedatolisib with fulvestrant, with or without palbociclib
- source indication text
- FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor -positive, human epidermal growth factor receptor 2 -negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
- match phrase
- breast cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-cfcc707359fdc22f
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-09-04 · Etcamah (camizestrant) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- fda-e2bb1179d3531239
- event date
- 2026-09-04
- event kind
- accelerated-approval
- drug or regimen
- Etcamah (camizestrant)
- source indication text
- In combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test
- match phrase
- breast cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-086f7c231b1cbc70103f
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-09-04 · camizestrant with a CDK4/6 inhibitor · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- event id
- notice-17b005184d4e1293
- event date
- 2026-09-04
- event kind
- approval-notification
- drug or regimen
- camizestrant with a CDK4/6 inhibitor
- source indication text
- FDA approved camizestrant, an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor for adults with hormone receptor -positive, human epidermal growth factor receptor 2 -negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
- match phrase
- breast cancer
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-29ff88a8fe51d0cc
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- binding id
- ncit-C118809
- source collection
- ncit-concept
- source key
- C118809
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- binding id
- ncit-C4872
- source collection
- ncit-concept
- source key
- C4872
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-breast-cancer
- binding id
- ncit-C9335
- source collection
- ncit-concept
- source key
- C9335
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice